Breaking AI & Tech News Analyzed

The Financial Conduct Authority (FCA) has accused Crispin Odey, a former hedge fund manager, of attempting to manipulate a victim of sexual assault into silence. According to evidence presented in court, Odey sent a text to his former employee in January 2022, warning her that the FCA could question her about him.Odey, who has previously accepted that he groped the woman without her consent in 2005, claimed he was under the influence of sedatives at the time. He now faces a number of sexual harassment allegations and has launched a £79m libel lawsuit against the Financial Times.The FCA's lawyer, Clare Sibson, argued that Odey was trying to manipulate the victim into silence and had a clear motive to discourage her from providing her account to the FCA. Odey, however, claimed he only wanted to ensure the woman would "tell the truth".The hearing continues, with Odey hoping to overturn the FCA's decision to ban him from the UK's financial services industry. In addition to the libel lawsuit, Odey is also facing civil personal injury claims by five women, including one who accused him of rape.

Rapper Jay-Z recently spoke out about a sexual assault lawsuit filed against him and Sean 'Diddy' Combs' in 2024. The lawsuit alleged that both men raped a 13-year-old girl at a party in 2000, which both Jay-Z and Combs vehemently denied.In a recent interview with GQ, Jay-Z explained why he chose to fight the lawsuit rather than settle. He stated, 'I can’t take a settlement – it ain’t in my DNA.' He further emphasized that settling would have been difficult for him and his family, particularly his wife Beyoncé.Jay-Z expressed that he was 'heartbroken' and 'angry' when the allegations first emerged. He described the experience as 'really hard' and mentioned that he hadn't felt 'uncontrollable anger' in a long time. The rapper emphasized the importance of being certain before making such serious accusations against someone.The lawsuit was voluntarily dismissed in February 2025. Jay-Z's attorney, Alex Spiro, previously described the claims as 'provably, demonstrably false' and highlighted an 'impossible timeline.'In addition to discussing the lawsuit, Jay-Z touched on other topics, including the beef between Kendrick Lamar and Drake and what he described as a 'right-wing agenda to silence voices in the hip-hop community.' He expressed concern about the negative impact of such conflicts on social media and the involvement of people's families.Jay-Z also reflected on 30 years since the release of his debut album Reasonable Doubt, which he will celebrate with two shows at New York's Yankee Stadium in July.

Crispin Odey, a 67-year-old hedge fund tycoon, appeared in a London courtroom on the first day of a three-week trial to challenge the Financial Conduct Authority's (FCA) decision to ban him from the UK's financial services industry. The ban was imposed due to allegations of sexual harassment made by several women. Odey testified that he did not recall cornering a female employee after a boozy lunch and saying to her 'I could attack you now'. However, the employee's diary entry, dated January 24, 2020, confirmed the incident, stating: 'Comes back from boozy lunch and corners me in the corridor. Him: I could attack you now. Me: Please don’t. Him: You could sue me for that.' Odey admitted to having groped a colleague's breasts without her consent in 2005, which he attributed to being under sedatives after root canal treatment. He claimed the woman accepted his apology and continued to work for the firm for another eight years. The FCA alleges that Odey showed a 'lack of integrity' by attempting to frustrate an investigation into allegations of sexual harassment. Odey denied these allegations, stating that he had attempted to have the FCA rule on whether he was fit and proper first. Odey is also facing a £79m libel lawsuit against the Financial Times and civil personal injury claims by five women, including one who accused him of rape. The hearing continues.

English and Welsh winemakers have experienced a significant surge in wine production in 2025, with 16.5m bottles produced across the UK, representing a 55% increase from the previous year. This growth is attributed to the hot, dry summer and an increase in vineyard plantings, resulting in the third-largest UK harvest. The 124,377 hectolitres of wine produced in 2025 is still below the 21.6m bottles produced in 2023, which was considered a bumper year. However, the industry has seen a substantial recovery from 2024, when production halved to 10.7m bottles due to high rainfall and disease in the grape crop. The 2025 harvest saw a notable increase in white wine production, which rose by 131% compared to 2024. Nicola Bates, chief executive of WineGB, expressed optimism about the quality and scale of the 2025 vintage, highlighting the skill and hard work of viticulturalists and winemakers. The growth of the industry is reflected in the 4% increase in vineyards registered with the Food Standards Agency (FSA) to 1,158, with the majority being commercial operators. The UK wine sector now employs over 10,000 people and has a value of £14bn. The industry has seen a 3% increase in vine plantings in 2025, covering an area of 4,357 hectares (10,700 acres).

Scientists have made a groundbreaking discovery that could lead to the development of new obesity drugs. By studying the unique metabolic abilities of pythons, researchers have identified a molecule that appears to play a crucial role in regulating appetite and weight loss. The molecule, called pTOS, was found to increase significantly in the blood of pythons after they eat, and when administered to obese mice, it led to a significant reduction in food intake and a 9% loss of body weight over 28 days. The discovery could lead to the development of new obesity drugs that work in a different way to existing medications, such as GLP-1 medications like Wegovy. Unlike these medications, which can have side effects such as nausea and stomach pain, pTOS appears to act on the brain's appetite centers, reducing food intake without these adverse effects. The researchers, led by Dr. Jonathan Long from Stanford University and Prof. Leslie Leinwand from the University of Colorado Boulder, published their findings in the journal Nature Metabolism. They believe that pTOS, which is naturally produced by the snake's gut bacteria and also found in human urine, could be a safe and effective treatment for obesity. While further research is needed before the findings can be applied clinically, the discovery is seen as a promising step towards the development of new obesity treatments. The study's results suggest that pTOS could be a potential therapeutic target for the treatment of obesity and related metabolic disorders.